"A Review of the Clinical Experience with AVAXIM(TM): An Inactivated Hepatitis A Vaccine "

According to an abstract submitted by the authors to the Fifth International Conference on Travel Medicine, held March 24-27, 1997, in Geneva, Switzerland, "A new formalin-inactivated hepatitis A vaccine (AVAXIM) has been developed by Pasteur Merieux Serums & Vaccine (P.M.sv.) from the hepatitis A virus (HAV) (GBM strain) cultured on human diploid cells. AVAXIM contains 160 enzyme linked immunoabsorbant assay (ELISA) antigen units per dose, absorbed onto 0.3 mg of aluminum hydroxide, in a total volume of 0.5 mL. In clinical trials involving more than 3,000 persons who were 16 years of age, adverse reactions were usually mild and limited to the first few days after vaccination, and they...

Want to see the full article?

• Purchase this article for only $3.00